EP
CSTL icon

Essential Partners’s Castle Biosciences CSTL Stock Holding History

Essential Partners’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.53K Buy
190
+61
+47% +$1.36K ﹤0.01% 1592
2026
Q1 		$3.17K Sell
129
-5
-4% -$164 ﹤0.01% 1797
2025
Q4 		$5.21K Buy
134
+11
+9% +$355 ﹤0.01% 1409
2025
Q3 		$2.8K Buy
+123
New +$2.5K ﹤0.01% 1669

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Essential Partners's CSTL Position: Q2 2026 in Review

Essential Partners increased its Castle Biosciences (CSTL) stake by 47% in Q2 2026, buying an estimated $1.36K and bringing the position to 190 shares worth $4.53K. The position accounts for ﹤0.01% of the portfolio, ranked #1592.

Essential Partners first reported a position in CSTL in Q3 2025 and has held it in 4 quarters since. The position peaked at $5.21K in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Essential Partners held 190 shares of Castle Biosciences worth $4.53K as of Q2 2026.
  • Essential Partners bought 61 Castle Biosciences shares in Q2 2026, an estimated $1.36K.
  • Castle Biosciences made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1592 holding.
  • Essential Partners first reported a position in Castle Biosciences in Q3 2025 and has held it in 4 quarters since.
  • Essential Partners's Castle Biosciences position peaked at $5.21K in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.